D-1386-2019 Class III Terminated

Recalled by Fresenius Kabi USA, LLC — Grand Island, NY

FDA drug recall D-1386-2019 was initiated by Fresenius Kabi USA, LLC on May 22, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is terminated (terminated Jan 28, 2021). Affected quantity: 11,981 units.

Recall details

Product Type
Drugs
Report Date
Jun 19, 2019
Initiation Date
May 22, 2019
Termination Date
Jan 28, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,981 units

Product description

Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047, NDC 63323-374-20

Reason for recall

Failed Impurities/Degradation Specifications.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 6018699, Exp. 12/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1386-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1386-2019. Report a data issue: hello@regdatalab.com.